Showing results (1-10 of 117) with videos related to
Sort By:
Pageof 12
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 24, 2025
[Recent Therapeutic Development Targeting KRAS Mutations in Colorectal Cancer]Hiromichi Ebi, Sachiyo ShirakawaSmall Gtpases|July 9, 2016
Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancerHidenori Kitai, Hiromichi EbiCancer Science|December 27, 2024
Mechanisms of Resistance to KRAS Inhibitors: Cancer Cells' Strategic Use of Normal Cellular Mechanisms to AdaptNoritaka Tanaka, Hiromichi EbiNihon Rinsho. Japanese Journal of Clinical Medicine|March 22, 2002
[Rationale for Herceptin in the clinical use]Hiromichi Ebi, Yasutsuna SasakiJCO Precision Oncology|September 14, 2020
Precision Oncology and the Universal Health Coverage System in JapanHiromichi Ebi, Hideaki BandoGan to Kagaku Ryoho. Cancer & Chemotherapy|December 15, 2005
[Pharmacokinetic comparison of capecitabine and 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR)]Hironobu Minami, Hiromichi EbiOncology|August 11, 2025
Newly developed drugs for hepatocellular carcinoma expanded the use of systemic therapy: An interrupted time series analysis using an electronic medical record in JapanSachiyo Shirakawa, Takanori Yanai, Koji KawakamiCancers|October 23, 2021
Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant CancersYuta Adachi, Ryo Kimura, Kentaro Hirade, et al.BMC Surgery|July 16, 2020
Response to: "timing of administration of indocyanine green for fluorescence-guided surgery in pancreatic cancer: response to Shirakawa et al."Sachiyo Shirakawa, Hirochika Toyama, Masahiro Kido, et al.BMC Surgery|November 9, 2019
A prospective single-center protocol for using near-infrared fluorescence imaging with indocyanine green during staging laparoscopy to detect small metastasis from pancreatic cancerSachiyo Shirakawa, Hirochika Toyama, Masahiro Kido, et al.Pageof 12